ERBB2 and breast carcinoma: Interestingly, the authors of the referred study noted that the observed synergistic activity of KDM5 inhibitors with trastuzumab and lapatinib—two commonly used drugs to treat HER2+ positive breast cancer—was independent of its target, the KDM5 [303].